

March 6, 2024

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001**

**To,
The Manager – Listing
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our letter dated September 21, 2023 in relation to the sale of 91,895,379 equity shares (“**Sale Shares**”) representing 75.00% of the issued and paid-up equity share capital of Glenmark Life Sciences Limited (“**GLS**”), a subsidiary of the Company, to Nirma Limited (the “**Buyer**”) in accordance with the terms of the share purchase agreement dated September 21, 2023 among the Company, GLS and the Buyer (the “**Share Purchase Agreement**”).

Closing under the Share Purchase Agreement has been initiated; 67,389,994 equity shares representing 55% of the issued and paid-up equity share capital of GLS have been transferred by the Company to the Buyer; and closing will be complete upon the completion of the transfer of the remaining Sale Shares.

This is for your information and records.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

**Harish Kuber
Company Secretary & Compliance Officer**

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com